secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001193125-23-280240
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra completes Acer acquisition; issues stock, CVRs, and $6M registered direct offering
--------------------------------------------------------------------------------

- Acquisition of Acer closed Nov 17; Acer shareholders receive 0.1210 Zevra shares + one CVR per share.
- CVRs entitle holders to up to $76M upon achieving OLPRUVA net sales milestones ($35M-$200M) and regulatory approvals.
- Zevra raised ~$6M via registered direct offering of 1,382,489 shares + warrants at $4.34/unit; also issued 917,934 shares to cancel Acer warrant.
- Prior to merger, Zevra purchased Acer senior secured debt for $28.5M in cash, stock, and notes.
- OLPRUVA (FDA-approved for UCDs) adds commercial-stage asset; EDSIVO for vEDS in Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312523280240/0001193125-23-280240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312523280240/d209243d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-280240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer